Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

Pharmacotherapies of NAFLD: updated opportunities based on

NASH Target Development Service for DAG O-Acyltransferase (DGAT

Full article: Patent landscape for discovery of promising

Full article: Patent landscape for discovery of promising

Updates on novel pharmacotherapeutics for the treatment of

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Pharmacotherapies of NAFLD: updated opportunities based on

Medicina, Free Full-Text

MGAT2 inhibitor decreases liver fibrosis and inflammation in

Beyond triglyceride synthesis: the dynamic functional roles of

New Drugs on the Block—Emerging Treatments for Nonalcoholic

Beyond triglyceride synthesis: the dynamic functional roles of

Frontiers New insights into the role of dietary triglyceride